CN1218882C - Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same - Google Patents
Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same Download PDFInfo
- Publication number
- CN1218882C CN1218882C CN 200310106498 CN200310106498A CN1218882C CN 1218882 C CN1218882 C CN 1218882C CN 200310106498 CN200310106498 CN 200310106498 CN 200310106498 A CN200310106498 A CN 200310106498A CN 1218882 C CN1218882 C CN 1218882C
- Authority
- CN
- China
- Prior art keywords
- ferric oxide
- magnetic
- tumour
- caloricity
- magnetic powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 38
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 7
- 230000020169 heat generation Effects 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000005291 magnetic effect Effects 0.000 claims abstract description 71
- 239000006247 magnetic powder Substances 0.000 claims abstract description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000008367 deionised water Substances 0.000 claims abstract description 6
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 6
- 238000000015 thermotherapy Methods 0.000 claims description 31
- 239000004615 ingredient Substances 0.000 claims description 9
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000011790 ferrous sulphate Substances 0.000 claims description 5
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 2
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 11
- 238000001914 filtration Methods 0.000 abstract description 4
- 230000008021 deposition Effects 0.000 abstract 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract 2
- 239000011259 mixed solution Substances 0.000 abstract 2
- 239000013049 sediment Substances 0.000 abstract 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract 1
- 239000012267 brine Substances 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Abstract
The present invention relates to ferric oxide magnetic powder with high magnetic hysteresis heat generation ability for the use of thermomagnetic therapy of tumor, and a preparation method thereof. The ferric oxide magnetic powder contains the following main ingredients: ferroferric oxide, or ferric oxide, or ferroferric oxide and ferric oxide; in the chemical composition of the ferric oxide magnetic powder, the content of ferrum is from 69.0 to 72.4%, the content of oxygen is from 27.6 to 31.0%, the magnetic hysteresis heat generation ability is from 50 to 2000 W/g Fe, and the particle diameter is from 50 nm to 100 mu m. The preparation method of the ferric oxide magnetic powder comprises the following steps: ferrous brine solution is heated to 60 DEG C to 80 DEG C; water solution of sodium hydroxide is added; the pH value of the mixed solution is regulated to be from 6 to 8; the mixed solution is stirred, oxygen is added, and a reaction is accelerated; after more than 1 minute, through the reaction, ferric oxide sediment is prepared; through filtration or in other modes, the ferric oxide sediment is separated, and a deposition product is obtained; the deposition product is washed by deionized water, is filtered or separated in other modes, is dried, etc., and the ferric oxide magnetic powder with high magnetic hysteresis heat generation ability for the use of thermomagnetic therapy of tumor is prepared.
Description
Technical field
The present invention relates to tumour magnetic thermotherapy with iron oxide magnetic powder of high magnetic hysteresis caloricity and preparation method thereof.
Background technology
Tumour magnetic thermotherapy is that a kind of magnetic hysteresis of utilizing the magnetic materials such as iron oxide magnetic powder that import the in-vivo tumour position to produce under the effect of external alternating magnetic field is given birth to heat effect heating tumour, utilize tumour cell poor heat resistance selectively killing tumour cell, the thermotherapy novel method of safe and effective treatment tumour.But the iron oxide magnetic powder magnetic hysteresis caloricity of using in the research of tumour magnetic thermotherapy is lower at present, need more magnetic and more powerful magnetic thermotherapy treatment instrument during application, almost there is not clinical value, the low development that is also restricting mediation and master, the novel powder medicament of passive target equimagnetic thermotherapy iron oxide magnetic and treatment technology of iron oxide magnetic powder magnetic hysteresis caloricity in addition, tumour magnetic thermotherapy technology presses for the iron oxide magnetic powder of high magnetic hysteresis caloricity.
Summary of the invention
The objective of the invention is to provide tumour magnetic thermotherapy iron oxide magnetic powder and preparation method thereof of a kind of high magnetic hysteresis caloricity at above-mentioned weak point, by adding the mode chemical preparation of oxygen accelerated reaction, main component is Z 250 or ferric oxide or the iron oxide magnetic powder magnetic be made up of Z 250 and ferric oxide, magnetic hysteresis caloricity height, have biological degradability and avirulent iron oxide magnetic powder, solve the above-mentioned present tumour magnetic thermotherapy lower problem of iron oxide magnetic powder magnetic hysteresis caloricity.
The tumour magnetic thermotherapy of high magnetic hysteresis caloricity is to adopt following scheme to realize with iron oxide magnetic powder and preparation method thereof: the tumour magnetic thermotherapy of high magnetic hysteresis caloricity is formed with iron oxide magnetic powder main component Z 250 or ferric oxide or by Z 250 and ferric oxide, and iron level is that 69.0-72.4%, oxygen level are that 27.6-31.0%, magnetic hysteresis caloricity reach 50-2000W/gFe, particle diameter is 5nm～100 μ m in its chemical ingredients.
The tumour magnetic thermotherapy iron oxide magnetic powder, preparation method thereof of high magnetic hysteresis caloricity: perferrite solution is heated to 60-80 ℃ and add aqueous sodium hydroxide solution and make the pH value of mixing solutions transfer to 6-8, under agitation add the oxygen accelerated reaction, make the iron oxide precipitation thing through reaction more than 1 minute, obtain precipitated product through separation, then with precipitated product process deionized water wash, separate, it is 5nm～100 μ m that drying process is made particle diameter, major ingredient is Z 250 or ferric oxide, or the iron oxide magnetic powder of forming by Z 250 and ferric oxide, iron level is 69.0-72.4% in its chemical ingredients, oxygen level is 27.6-31.0%, the magnetic hysteresis caloricity reaches 50-2000W/gFe, the tumour magnetic thermotherapy iron oxide magnetic powder that has biological degradability and have no side effect.Ferrous salt can adopt a kind of in ferrous sulfate, Iron nitrate, the iron protochloride.
The tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of the present invention iron oxide magnetic powder magnetic hysteresis caloricity height, can reach 50-2000W/gFe, can be widely used in the tumour magnetic thermotherapy as a kind of iron oxide magnetic powder that imports the in-vivo tumour position, under the effect of external alternation roller property, produce magnetic hysteresis and give birth to heat effect heating tumour, the selectively killing tumour cell is treated tumour safely and effectively.The characteristics that the tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of the present invention has biological degradability and has no side effect with iron oxide magnetic powder, its manufacture craft is simple, reliable in quality.
Embodiment
The invention will be further described below with reference to embodiment.
The tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of embodiment 1, particle diameter 5-10nm prepares with iron oxide magnetic powder
The ferrous sulfate aqueous solution of concentration 0.6ml/L is heated to 60-80 ℃ and the aqueous sodium hydroxide solution that adds concentration 2.4mol/L makes the pH value of mixing solutions transfer to 6.4, under stirring fast, add oxygen and make the iron oxide precipitation thing at the aqueous solution, get precipitated product through 1 minute to 1 hour time response after-filtration, then with precipitated product process deionized water wash, filter, it is 5-10nm that technologies such as vacuum-drying are made particle diameter, iron level is 69.0-72.4%'s in the chemical ingredients, oxygen level is 27.6-31.0%, the magnetic hysteresis caloricity reaches the tumour magnetic thermotherapy iron oxide magnetic powder of 700-2000W/gFe.
The tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of embodiment 2, particle diameter 50-100nm prepares with iron oxide magnetic powder
The ferrous sulfate aqueous solution of concentration 1.6ml/L is heated to 60-80 ℃ and the aqueous sodium hydroxide solution that adds concentration 2.4mol/L makes the pH value of mixing solutions transfer to 7, under stirring fast, add oxygen and make the iron oxide precipitation thing at the aqueous solution, get precipitated product through 30 clocks to 2 a hour time response after-filtration, then with precipitated product process deionized water wash, filter, it is 50-100nm that technologies such as vacuum-drying are made particle diameter, iron level is 69.0-72.4%'s in the chemical ingredients, oxygen level is 27.6-31.0%, the magnetic hysteresis caloricity is the tumour magnetic thermotherapy iron oxide magnetic powder of 100-500W/gFe.
The tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of embodiment 3, particle diameter 10-100 μ m prepares with iron oxide magnetic powder
The ferrous sulfate aqueous solution of concentration 1.6ml/L is heated to 60-80 ℃ and the aqueous sodium hydroxide solution that adds concentration 2.4mol/L makes the pH value of mixing solutions transfer to 7.4, under stirring fast, add oxygen and make the iron oxide precipitation thing at the aqueous solution, get precipitated product through time response after-filtration more than 6 hours, then with precipitated product process deionized water wash, filter, it is 10-100 μ m that technologies such as vacuum-drying are made particle diameter, iron level is 69.0-72.4%'s in the chemical ingredients, oxygen level is 27.6-31.0%, the magnetic hysteresis caloricity is the tumour magnetic thermotherapy iron oxide magnetic powder of 50-100W/gFe.
The tumour magnetic thermotherapy of embodiment 4, the high magnetic hysteresis caloricity biological degradability and the toxic side effect of iron oxide magnetic powder
It is subcutaneous that the aqua that the tumour magnetic thermotherapy of the above-mentioned high magnetic hysteresis caloricity of 50mg is made with iron oxide magnetic powder is injected to nude mice, observe to find injection after 30 days all magnetics all absorbed by nude mice, body weight and the untoward reaction observation that nude mice is carried out simultaneously shows no obvious abnormalities, after nude mice is put to death, core, vitals such as brain, spleen, kidney, intestines, liver do pathologic finding, show no obvious abnormalities.Studies show that, the tumour magnetic thermotherapy that adopts above-mentioned high magnetic hysteresis caloricity is carried out the magnetic thermotherapy treatment with iron oxide magnetic powder only needs 1-20mg (much smaller than 50mg) magnetic can make tumour heating temperature to effectively killing tumour cell and treatment tumour more than 42-43 ℃ usually, be not difficult to find out that from the secondary experimental result of above-mentioned preliminary poison the tumour magnetic thermotherapy of the high magnetic hysteresis caloricity of the present invention has biological degradability with iron oxide magnetic powder and has no side effect.
Claims (3)
1, a kind of tumour magnetic thermotherapy iron oxide magnetic powder of high magnetic hysteresis caloricity, it is characterized in that main component is Z 250 or ferric oxide or is made up of Z 250 and ferric oxide that iron level is that 69.0-72.4%, oxygen level are that 27.6-31.0%, magnetic hysteresis caloricity reach 50-2000W/gFe, particle diameter is 5nm～100 μ m in its chemical ingredients.
2, the tumour magnetic thermotherapy iron oxide magnetic powder, preparation method thereof of the described high magnetic hysteresis caloricity of claim 1, it is characterized in that perferrite solution is heated to 60-80 ℃ and add aqueous sodium hydroxide solution and make the pH value of mixing solutions transfer to 6-8, under agitation add the oxygen accelerated reaction, make the iron oxide precipitation thing through reaction more than 1 minute, obtain precipitated product through separation, then with precipitated product process deionized water wash, separate, it is 5nm～100 μ m that drying process is made particle diameter, major ingredient is Z 250 or ferric oxide, or the iron oxide magnetic powder of forming by Z 250 and ferric oxide, iron level is 69.0-72.4% in its chemical ingredients, oxygen level is 27.6-31.0%, the magnetic hysteresis caloricity reaches 50-2000W/gFe.
3, the tumour magnetic thermotherapy iron oxide magnetic powder, preparation method thereof of high magnetic hysteresis caloricity according to claim 2 is characterized in that described ferrous salt is a kind of in ferrous sulfate, Iron nitrate, the iron protochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310106498 CN1218882C (en) | 2003-12-03 | 2003-12-03 | Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310106498 CN1218882C (en) | 2003-12-03 | 2003-12-03 | Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546385A CN1546385A (en) | 2004-11-17 |
| CN1218882C true CN1218882C (en) | 2005-09-14 |
Family
ID=34334206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310106498 Expired - Fee Related CN1218882C (en) | 2003-12-03 | 2003-12-03 | Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1218882C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100352866C (en) * | 2005-06-08 | 2007-12-05 | 刘世琦 | Method for producing iron oxide black |
| CN1772303A (en) * | 2005-10-25 | 2006-05-17 | 朱宏 | Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor |
| CN111642652A (en) * | 2020-06-30 | 2020-09-11 | 武汉合缘绿色生物股份有限公司 | Feed additive for regulating intestinal function of poultry and preparation method thereof |
-
2003
- 2003-12-03 CN CN 200310106498 patent/CN1218882C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1546385A (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108187072A (en) | The nano material of manganese dioxide and preparation method and application that albumin is stablized | |
| EP0888545A1 (en) | Super-paramagnetic particles with increased r 1? relaxivity, processes for producing said particles and use thereof | |
| KR101172495B1 (en) | The preparation method of engineered superparamagnetic magnesium ferrite and its biomedical use | |
| CN101417822A (en) | Method for preparing super paramagnetic mesoporous ferriferrous oxide nano particle | |
| CN105271433B (en) | Hydrothermal synthesis preparation method of zinc doped superparamagnetic ferroferric oxide nano particle | |
| CN104941607B (en) | Styrene resin adsorption agent for clearing high beta2 microglobulin in blood | |
| CN113181211A (en) | Fe2O3@ TA-Pt nano composite material and preparation method and application thereof | |
| CN1218882C (en) | Ferric oxide with high magnetic-hysteresis heat generation ability for the use of tumour thermomagnetic therapy and method for preparing the same | |
| CN111228489A (en) | Ferroferric oxide bismuth sulfide nano composite material and preparation and application thereof | |
| CN102552945B (en) | Surface modification method of magnetic iron oxide nano-particles | |
| Guan et al. | High-efficiency and safe sulfur-doped iron oxides for magnetic resonance imaging-guided photothermal/magnetic hyperthermia therapy | |
| CN104623659A (en) | Preparation method of multifunctional probe for tumor thermotherapy as magnetic resonance imaging contrast agent | |
| Xu et al. | Doping engineering and functionalization of iron oxide nanoclusters for biomedical applications | |
| CN111068051B (en) | Diagnosis and treatment integrated nanoprobe based on copper phthalocyanine molecule and preparation and application thereof | |
| WO2020057086A1 (en) | Fe3+/2+-no donor mixed-valence coordination polymer and application thereof | |
| Aronovitz et al. | Ferritin iron mineralization and storage: from structure to function | |
| CN106800315B (en) | A kind of method that ionic liquid assisted microwave synthesis radiation method synthesizes extra small magnetic Nano cluster | |
| CN114015064B (en) | Porphyrin MOF nanosheet with ultrasonic stimulus response, and preparation method and application thereof | |
| WO2022067885A1 (en) | Application of doped titanium dioxide in manufacturing of sonosensitizer | |
| CN109809429B (en) | Modified clinoptilolite and preparation method and application thereof | |
| WO1990001939A1 (en) | Agent for thermotherapy | |
| CN101708866A (en) | Superparamagnetic water-soluble manganous ferrite nano-particle and application thereof | |
| CN108996552B (en) | Method for extracting magnetic ferroferric oxide nanoparticles from traditional Chinese medicine magnetite, product and application thereof | |
| CN112426527B (en) | Two-dimensional red phosphorus nano material with anti-tumor function | |
| CN111087376B (en) | Gadolinium-doped rose bengal nanodots and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING WUSHENG NANO TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: NANJING UNIVERSITY OF TECHNOLOGY Effective date: 20150303 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 210024 NANJING, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150303 Address after: 210024 block E, No. 177, Guangzhou Road, Jiangsu, Nanjing, China Patentee after: Nanjing Wu Sheng Nano Technology Co.,Ltd. Address before: 210009 Gulou District, Jiangsu, Nanjing new model road, No. 5 Patentee before: Nanjing University of Technology |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050914 |